Spilled Blood: CSL & Talecris Terminate Their Merger Deal In Face of FTC Lawsuit
This article was originally published in PharmAsia News
Executive Summary
Caving in to opposition from the Federal Trade Commission, CSL Limited has scuttled its $3.1 billion deal to acquire Talecris Biotherapeutics, saying it was not worth the money and time to battle the agency in court